The tumor foci and volumes of CD133+ treated by DBH+IR alone or DBH+IR combined with BCL-2 siRNA were significantly decreased compared to those of CD133+ and only IR-treated CD133+ (p<0.01; Fig. 8A). Here, BCL2 is linked to neoplasm.